Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
09/2013
09/26/2013US20130251805 Low viscosity liquid dosage forms
09/26/2013US20130251804 Method to improve the safety of handling of high potency drugs in solid dosage forms without changing their efficacy
09/26/2013US20130251803 Once daily formulation of lacosamide
09/26/2013US20130251802 Tamper resistant dosage forms
09/26/2013US20130251801 Tamper resistant dosage forms
09/26/2013US20130251800 Tamper resistant dosage forms
09/26/2013US20130251799 Tamper resistant dosage forms
09/26/2013US20130251798 Tamper resistant dosage forms
09/26/2013US20130251795 Pharmaceutical compositions containing a biguanide and a low dose antidiabetic agent
09/26/2013US20130251793 Pharmaceutical composition comprising phentermine and topiramate
09/26/2013US20130251791 Composition comprising a benzimidazole and process for its manufacture
09/26/2013US20130251790 Low Dose Pharmaceutical Composition Comprising Zanamivir
09/26/2013US20130251789 Tamper-resistant oral opioid agonist formulations
09/26/2013US20130251787 Treatment of Pulmonary Hypertension with Leukotriene Inhibitors
09/26/2013US20130251785 Method and composition for treating cystitis
09/26/2013US20130251782 Topical application of ingenol mebutate with occlusion
09/26/2013US20130251781 Composition and Method for Treating Connective Tissue Damage
09/26/2013US20130251779 New product
09/26/2013US20130251765 Modified pectins, compositions and methods related thereto
09/26/2013US20130251763 Transdermal compositions
09/26/2013US20130251761 Organic compounds
09/26/2013US20130251760 Transdermal Analgesic Systems with Reduced Abuse Potential
09/26/2013US20130251757 Drug Loaded Polymeric Nanoparticles and Methods of Making and Using Same
09/26/2013US20130251753 Treatment of infection
09/26/2013US20130251739 Proteins expressed by mycobacterium tuberculosis and not by bcg and their use as diagnostic reagents and vaccines
09/26/2013US20130251734 Use of tam receptor inhibitors as antimicrobials
09/26/2013US20130251732 Targeting of cyp1b1 in the treatment of head and neck cancer and lung cancer
09/26/2013US20130251730 Compounds and Mixtures Influencing Inflammatory States
09/26/2013US20130251709 Methods using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of acute myelogenous leukemia
09/26/2013US20130251702 Method for screening compounds for treating sepsis targeting nod2 signalling pathway and composition for treating sepsis comprising nod2 signalling pathway inhibitors
09/26/2013US20130251697 Novel nasal spray
09/26/2013US20130251696 Antioxidant Composition for Reducing Oxidative Stress Ascribable to the Treatment with Hormonal Contraceptive Drugs
09/26/2013US20130251685 Injectable Cross-Linked Polymeric Preparations and Uses Thereof
09/26/2013US20130251682 Oligosaccharide composition for treating skin diseases
09/26/2013US20130251678 Bid dosage regimen for deb025
09/26/2013US20130251673 Hepatitis b antiviral agents
09/26/2013US20130251671 Gaba agonists in the treatment of disorders associated with metabolic syndrome and gaba combinations in treatment or prophylaxis of type i diabetes
09/26/2013US20130251667 Amide dendrimer compositions
09/26/2013US20130251649 Method for preventing or treating skin tumor
09/26/2013US20130251644 Cyclodextrin-Based Microemulsions, and Dermatological Uses Thereof
09/26/2013US20130251643 Abuse-proofed oral dosage form
09/26/2013US20130251635 High-dose glycine as a treatment for obsessive-compulsive disorder and obsessive-compulsive spectrum disorders
09/26/2013US20130251634 Methods and compositions for protection of cells and tissues from computed tomography radiation
09/26/2013US20130251631 Low molecular weight thyroid stimulating hormone receptor (tshr) agonists
09/26/2013US20130249140 Method of producing a solid preparation
09/26/2013US20130249131 Process for producing pellets for pharmaceutical compositions
09/26/2013US20130248448 Citrate-Based Dialysate Chemical Formulations
09/26/2013DE102012204823A1 Drug useful e.g. for preparing composition and dietary supplement e.g. functional food and dietary product, and treating and/or preventing infertility and menstrual disorders, and increasing fertility, comprises ecdysone derivatives
09/26/2013CA2861056A1 Combination therapy (vemrufenib and a mdm2 inhibitor) for the treatment proliferative disorders
09/25/2013EP2641969A1 Novel therapeutic target for the prevention of tumour metastasis
09/25/2013EP2641968A2 Orally administered pharmaceutical composition and preparation method thereof, for the prevention and treatment of irritable bowel syndrome, comprising an intestinal motility modifier and -d-galactosidase
09/25/2013EP2641918A2 Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (PCSK9)
09/25/2013EP2641917A2 Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (PCSK9)
09/25/2013EP2641907A1 Preparation of modulators of 5-HT receptors
09/25/2013EP2641906A1 Tofa analogs useful in treating dermatological disorders or conditions
09/25/2013EP2641904A1 Flavone derivatives and their use
09/25/2013EP2641901A1 Novel microbiocides
09/25/2013EP2641900A1 Novel polymorphic Crystal forms of 5-(2-{[6-(2,2-difluoro-2-phenylethoxy) hexyl]amino}-1-(R)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one, heminapadisylate as agonist of the ß2 adrenergic receptor.
09/25/2013EP2641891A1 Pkc- activator
09/25/2013EP2641615A2 Compositions comprising dietary fat complexer and methods for their use
09/25/2013EP2641614A1 Pharmaceutical preparation integrated with microneedles for skin treatment
09/25/2013EP2641607A1 A mixture of polar glycolipids for use in the treatment of pain and COPD
09/25/2013EP2641605A1 Novel polymer derivative of cytidine metabolism antagonist
09/25/2013EP2641604A2 Composition containing styraxlignolide a or the aglycone thereof as an active ingredient for preventing or treating asthma
09/25/2013EP2641603A1 Pharmaceutical formulation having neuroprotective activity
09/25/2013EP2641602A1 Method for treating gynecological diseases
09/25/2013EP2641601A1 Methods of treating multiple myeloma using combination therapies based on HuLuc63 with bortezimob
09/25/2013EP2641600A1 Methods of Treating Multiple Myeloma Using Combination Therapies based on Anti-CS1 Antibodies
09/25/2013EP2641599A1 Composition of an oral dosage form of vitamin E esters combination with enhanced antioxidant activity.
09/25/2013EP2641598A2 Orally administered pharmaceutical composition for the treatment of irritable bowel syndrome, comprising an intestinal motility modifier, an agent that prevents gas retention, and digestive enzymes, and preparation method thereof
09/25/2013EP2641597A1 Therapeutic or prophylactic agent for corneal epithelium disorders and/or conjunctival epithelium disorders
09/25/2013EP2641596A1 Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders
09/25/2013EP2641595A1 Sublingual fentanyl spray
09/25/2013EP2641594A2 Enteric coated solid pharmaceutical compositions for proton pump inhibitors
09/25/2013EP2641593A2 Tablets
09/25/2013EP2641592A1 Pharmaceutical formulation comprising bendamustine
09/25/2013EP2641591A1 Synthesis of Starch Based Bioadhesive Polymers and Applications in Drug Carrier Systems
09/25/2013EP2641590A1 Pharmaceutical compositions comprising imidazoquinolin(amines) and derivatives thereof suitable for local administration
09/25/2013EP2640847A1 Markers for acute kidney injury and uses thereof
09/25/2013EP2640735A1 Antibacterial amiinoglycoside analogs
09/25/2013EP2640734A1 Aminoglycosides and uses thereof in treating genetic disorders
09/25/2013EP2640731A1 Imidazole derivatives as pde10a enzyme inhibitors
09/25/2013EP2640729A1 Inhibitors of hiv replication
09/25/2013EP2640728A1 Novel monensin derivatives for the treatment and prevention of protozoal infections
09/25/2013EP2640727A1 Alaninyl maytansinol antibody conjugates
09/25/2013EP2640724A1 Novel indolizine derivatives, and preparation and therapeutic use thereof
09/25/2013EP2640723A1 Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors
09/25/2013EP2640722A1 Pyrazolopyridines and pyrazolopyridines and their use as tyk2 inhibitors
09/25/2013EP2640721A2 Agonists that enhance binding of integrin-expressing cells to integrin receptors
09/25/2013EP2640720A2 Bifunctional molecules with antibody-recruiting and entry inhibitory activity against the human immunodeficiency virus
09/25/2013EP2640719A2 Antiviral compounds
09/25/2013EP2640718A1 Substituted sodium-1h-pyrazole-5-olate
09/25/2013EP2640716A1 Cyclic amide compounds and their use in the treatment of disease
09/25/2013EP2640715A1 Quinoline derivatives as pik3 inhibitors
09/25/2013EP2640712A1 2-piperazin-1-yl-4h-1,3-benzothiazin-4-one derivatives and their use for the treatment of mammalian infections
09/25/2013EP2640709A2 Pyrimidine hydroxy amide compounds as protein deacetylase inhibitors and methods of use thereof
09/25/2013EP2640708A1 Heterocycle amines and uses thereof
09/25/2013EP2640705A2 Novel antiviral compounds
09/25/2013EP2640704A1 Nampt inhibitors
09/25/2013EP2640703A1 Heterocyclic compounds as imaging probes of tau pathology
1 ... 550 551 552 553 554 555 556 557 558 559 560 561 562 563 564 565 566 567 568 569 570 ... 7860